.jpg)
.jpg)
.jpeg)
Digital ArchiveThis story is part of our historical records. While preserved for reference, some details and facts may have evolved since its original publication 6 months ago.
MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Life Itself Conference – MycoMedica Life Sciences, PBC, a new company focused on developing and delivering fungi-based therapeutic drugs to prevent and treat psychiatric and neurological disorders, today announced it has raised $60 million in funding led by Obvious Ventures, True Ventures and Kittyhawk Ventures. The proceeds from the financing...
B
Business
NEWS CARD
“MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders”
Read more onthebizzstories.com
2 Jun 2022
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Life Itself Conference – MycoMedica Life Sciences, PBC, a new company focused on developing and delivering fungi-based therapeutic drugs to prevent and treat psychiatric and neurological disorders, today announced it has raised $60 million in funding led by Obvious Ventures, True Ventures and Kittyhawk Ventures. The proceeds from the financing will be used to advance the company’s next stage of operations on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the Stamets Stack.
historyThis is an archived post. The information provided may be outdated.
